JPRN-UMIN000007648已完成2 期
A phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab for node-positive breast cancer - EC-wnabPTX as NAC PII
Tokyo Women's Medical University0 个研究点目标入组 56 人开始时间: 2012年4月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Severe complications history of hypersensitivity reaction for important drug in this study Bilateral breast cancer Inflammatory breast cancer Pregnant or nursing women
研究者
相似试验
招募中
2 期
A phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancerBreast cancerJPRN-UMIN000013886Tokyo Women's Medical University30
进行中（未招募）
不适用
Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) + sorafenib followed by paclitaxel (P) + sorafenib in women with previously untreated primary breast cancer - SofiaWomen with previously untreated primary breast cancer.MedDRA version: 9.1Level: LLTClassification code 10057654Term: Breast cancer femaleEUCTR2007-000124-41-DEGBG Forschungs GmbH36
已完成
2 期
Phase II study of Neoadjuvant Eribulin followed by FEC for operable triple-negative breast cancerBreast cancerJPRN-UMIN000014163ational Cancer Center Hospital43
已完成
2 期
Phase II trial of Epirubicin / Cyclophosphamide (EC) followed by Nab-paclitaxel as neoadjuvant chemotherapy for node positive breast cancerBreast CancerJPRN-UMIN000009853Dokkyo Medical University23
已完成
2 期
Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast CancerBreast CancerNCT00548899German Breast Group36